Bristol-Myers Squibb reports second quarter 2013 financial results Bristol-Myers Squibb Business today reported outcomes for the second one fourth of 2013 highlighted by the resubmission of Forxiga in the U.S., the completion of regulatory filings for Eliquis and Metreleptin in the U features of malegra .S. In addition, the ongoing company adjusted GAAP EPS and non-GAAP EPS guidance for 2013. ‘In the second quarter, the power in the performance of a few of our key products, the essential data we offered across our portfolio and the key regulatory filings we made in the U.S. Reinforce our confidence as we build a solid foundation for future development,’ said Lamberto Andreotti, ceo, Bristol-Myers Squibb.
The Globe Wellness Organisation estimates this strain of the virus has recently killed 165 people world-wide, mainly in south-east Asia, since 2003 and has either killed or triggered millions of birds to be culled. The strain is usually transmitted to poultry by migrating wildfowl, and so far, almost all humans who have been infected worldwide have been around in close contact with infected birds. Experts believe the most likely source of infection is crazy birds but at present the vaccination of poultry is not being considered. It seems the turkeys at the farm had been too youthful to enter the food chain and no birds or generate had moved off the site.